Kyowa Kirin Co., Ltd. (KY4)

Overview

Kyowa Kirin Co., Ltd. is a globally recognized pharmaceutical company with a rich history of innovation and excellence in the healthcare industry. Based in Tokyo, Japan, the company was established in 1949 and has grown to serve multiple regions across the globe including Japan, the United States, Europe, Asia, and the Americas. Initially known as Kyowa Hakko Kirin Co., Ltd., it underwent a name change to Kyowa Kirin Co., Ltd. in June 2019. Kyowa Kirin is dedicated to the research, development, manufacturing, and marketing of pharmaceuticals across vital therapeutic areas such as oncology, nephrology, central nervous system, and immunology. Under the umbrella of Kirin Holdings Company, Limited, Kyowa Kirin leverages cutting-edge science and technologies to address complex health challenges and improve the quality of life for patients worldwide.

Products and Services

Kyowa Kirin boasts a diverse portfolio of healthcare solutions and innovative pharmaceuticals aimed at treating a wide range of diseases and conditions:

• ALLELOCK: An antihistamine agent designed for patients suffering from various types of allergies, providing relief from allergy symptoms.
• CONIEL: A calcium channel blocker indicated for the management of hypertension and angina pectoris, aiding in the improvement of patient heart conditions.
• Crysvita: A recombinant human monoclonal IgG1 antibody against fibroblast growth factor 23, revolutionizing the treatment of diseases linked to phosphate metabolism.
• ESPO: A glycoprotein and human erythropoietin for addressing anemia, enhancing the quality of life for patients by improving red blood cell count.
• NESP: An erythropoiesis-stimulating agent, serving as another crucial solution in the management of anemia, particularly in patients with chronic kidney disease.
• GRAN / Peglasta / Neulasta: Human colony-stimulating factors for chemotherapy-induced febrile neutropenia, significantly reducing infection risks for cancer patients.
• LUMICEF: A biological treatment for moderate to severe plaque psoriasis, offering relief and improving skin health for sufferers of this chronic condition.
• Moventig: A mu-opioid receptor antagonist for opioid-induced constipation, providing critical gastrointestinal relief for patients on opioid medication.
• Nouriast / Nourianz: An adenosine receptor antagonist for the treatment of Parkinson's disease, contributing to better management of neurodegenerative disease symptoms.
• ORKEDIA: An oral calcimimetics agent, advancing the treatment of conditions like secondary hyperparathyroidism by regulating calcium levels in the body.
• POTELIGEO: A humanized monoclonal antibody for CC chemokine receptor 4, serving as a targeted therapy for certain cancers.
• REGPARA: Used in the management of secondary hyperparathyroidism, assisting in the control of parathyroid hormone levels in patients with chronic kidney disease.
• Romiplate / Nplate: A genetically recombinant protein that stimulates the production of platelets through the activation of thrombopoietin receptors, key in the treatment of thrombocytopenia.

In collaboration with Amgen Inc., Kyowa Kirin is also developing KHK4083, an anti-OX40 fully human monoclonal antibody for atopic dermatitis, highlighting its commitment to addressing unmet medical needs through innovative therapies.